$YDES News

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Publishes Review Article Titled Beyond Bone Health: Exploring The ‘Heart–Brain–Bone’ Axis Modulated By Lipid-Soluble Nutrients

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

YD Bio's Subsidiary Enters Into Master Strategic Alliance Agreement With YC Biotech To Establish Taiwan-U.S. Dual-Core Regulatory Platform

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

YD Bio Limited Signs Binding LOI To Acquire Safe Save Medical Cell Sciences & Technology; Co Intends To Acquire 100% Of Equity Interest For Consideration Of $26.87M

YD Bio Limited Signs Binding LOI To Acquire Safe Save Medical Cell Sciences & Technology; Co Intends To Acquire 100% Of Equity Interest For Consideration Of $26.87M

YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations.

YDES is A Biotechnology Company on the Move